Telpoeptide is a novel drug that exerts its weight-loss effects primarily by simultaneously acting on glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
GIP is a hormone secreted by intestinal K cells and released after eating. It promotes insulin secretion, thereby helping to regulate blood sugar levels, and also has some influence on fat metabolism.
GLP-1, secreted by intestinal L cells, not only stimulates insulin secretion and inhibits glucagon secretion to lower blood sugar, but also delays gastric emptying, increases satiety, and reduces food intake.
Telpoeptide's dual agonistic effect on these two receptors synergistically enhances appetite control, reducing calorie intake. Furthermore, it promotes the catabolism of adipose tissue, increasing energy expenditure. Through this dual pathway of reducing calorie intake and increasing energy expenditure, it achieves weight loss.